Conference Coverage
Conference Coverage
PSA density predicts progression of low-risk prostate cancer during active surveillance
Key clinical point: At 5 years after diagnosis of low-risk prostate cancer, most men who undergo active surveillance do not require treatment....
Conference Coverage
Psoriasis patients post above-average cancer rates
Key clinical point: Rates of malignancy were higher among patients with psoriasis than in the general population. Major finding: The 5-year...
Conference Coverage
Know your risks when selling your practice
Conference Coverage
A third of follicular thyroid lesions of undetermined significance were malignant
Key clinical point: National estimates of FLUS malignancy may not apply to your institution.Major finding: Among 80 patients diagnosed with FLUS...
Conference Coverage
Firm policies help address staff who behave badly
Conference Coverage
VIDEO: ABT-199 alone and in combination shows promise against advanced CLL
Conference Coverage
FDA panel recommends against approval of ultrasound therapy for early prostate cancer
Conference Coverage
Look for nephrotoxicity in adult survivors of childhood cancer
Key clinical point: Today 1 in 570 young adults is a childhood cancer survivor, and many are on the road to chronic kidney disease.
Conference Coverage
Depth of molecular response factors into safe TKI withdrawal in CML
Key clinical point: Long-time TKI therapy can be stopped in chronic myeloid leukemia in deep molecular remission.
Conference Coverage
Depth of molecular response factors into safe TKI withdrawal in CML
Key clinical point: Long-time TKI therapy can be stopped in chronic myeloid leukemia in deep molecular remission.
Conference Coverage
ABT-199 rebounds in advanced CLL after tackling tumor lysis syndrome
Major finding: The overall response rate was 77% with ABT-199 monotherapy and 84% with the addition of rituximab in relapsed or refractory CLL....